Pathophysiology of increased visceral fat mass in relation to atherosclerosis and cardiometabolic diseases can be mainly explained by insulin resistance, subclinical inflammation, dysregulated adipokine secretion and increased release of fatty acids into the circulation, implying potential targets of therapy for fatty liver disease and metabolic comorbidities [40, 41]. The gene discussed is INS; the disease is fatty liver disease.